Loading
AtriCure, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Privitera Salvatore, was filed 31 May 2024.
Insider Decl.
654
Thresholds
n/a
Buy Volume
€735,432
7 ops. · all time
Sell Volume
€66M
156 ops. · all time
Who traded when
BuySaleSven Wehrwein5 sales
Vinayak Doraiswamy4 sales
Justin J. Noznesky3 sales
Karen Prange3 sales
Salvatore Privitera3 sales
Maggie Yuen2 sales
+2 other insiders
Since the insiders bought
- +51.7%Entry US$22.42 · Close at T+365 US$34.00
- -45.7%Entry US$77.50 · Close at T+365 US$42.12
- +78.9%Entry US$42.46 · Close at T+365 US$75.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate AtriCure, Inc. Buy (bullish), based on 9 analysts. Average price target: US$55.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,664 of 26,246 companies
40.2
score / 100
Value38
Quality42
FCF yld1.4%
Earn yld-0.4%
EV/EBITDA·
ROE2.2%
Gross mgn75%
Net mgn-2.1%
Debt/EBITDA4.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$57.67
Analyst consensus
9 analystsBuy
US$36.00Target US$55.78(-3%)US$65.00
Income statement
RevenueUS$534.5M
Gross profitUS$400.8M75% margin
EBITDAUS$16.2M3% margin
Net income-US$11.4M1.9% margin
Valuation
PER (trailing)274.6x
PER (forward)132.9x
P/Book5.7x
Beta1.25
Balance sheet & cash
Market capUS$2.9B
Total debtUS$73.4M
Free Cash FlowUS$42.3M
Debt / Equity14%
Profitability & ownership
ROE2.2%
ROA1.3%
% insiders3.8%
% institutions105.3%
Last declaration on 24 September 2026
Declarations654 total
4,519 shares@ US$60.000.0091% mcap10.5% of flowCommon StockSEC:0001336063-26-000010:0
4,519 shares@ US$60.000.0091% mcap57.8% of flowCommonSEC144:0001950047-26-009764
5,313 shares@ US$54.220.0098% mcap19.5% of flowCommon StockSEC:0001653877-26-000006:0
5,313 shares@ US$53.660.0096% mcap19.3% of flowCommonSEC144:0001959173-26-006879
3,657 shares@ US$55.000.0066% mcap3.0% of flowCommon StockSEC:0001336063-26-000008:0
3,657 shares@ US$55.000.0066% mcap42.2% of flowCommonSEC144:0001950047-26-009179
7,763 shares@ US$52.500.013% mcap15.6% of flowCommon StockSEC:0001336063-26-000006:0
9,370 shares@ US$48.890.015% mcap30.9% of flowCommon StockSEC:0001861996-26-000006:0
9,370 shares@ US$48.88910.015% mcap100.0% of flowCommonSEC144:0001950047-26-008582
3,564 shares@ US$38.800.0046% mcap21.2% of flowCommon StockSEC:0001566083-26-000006:0
3,500 shares@ US$38.420.0045% mcap24.5% of flowCommon StockSEC:0001796057-26-000010:0
3,500 shares@ US$38.41940.0045% mcap100.0% of flowCommonSEC144:0001950047-26-007681
3,564 shares@ US$39.000.0046% mcap21.3% of flowCommonSEC144:0001959173-26-005641
700 shares0Common StockSEC:0001230584-26-000008:0
4,000 shares0Common StockSEC:0001230584-26-000008:1
25,000 shares@ US$19.950.017% mcap21.8% of flowCommon StockSEC:0001205069-26-000005:0
25,000 shares@ US$37.840.032% mcap41.4% of flowCommon StockSEC:0001205069-26-000005:1
6,000 shares@ US$38.880.0079% mcap15.4% of flowCommon StockSEC:0001862458-26-000011:0
6,182 shares@ US$38.800.0081% mcap15.6% of flowCommon StockSEC:0001666600-26-000004:0
6,182 shares@ US$38.80330.0081% mcap15.6% of flowCOMMONSEC144:0001000275-26-000095
25,000 shares@ US$38.57780.032% mcap100.0% of flowCommonSEC144:0001950047-26-007344
6,000 shares@ US$38.87980.0079% mcap100.0% of flowCommonSEC144:0001950047-26-007345
636 sharesCommon StockSEC:0001230584-26-000006:0
636 sharesCommon StockSEC:0001336063-26-000004:0
527 sharesCommon StockSEC:0001565823-26-000006:0
25 of 654 declarations
About AtriCure, Inc.
Scott William Drake (Director) is at the heart of the largest moves at AtriCure, Inc.: a sale of EUR 2,494,197 on May 7, 2021, but also the two largest purchases, EUR 422,169 on November 17, 2020 and EUR 159,163 on March 1, 2018. Michael H. Carrel (President, CEO, & Director) sold EUR 2,192,682 on December 18, 2020 and Douglas J. Seith (Chief Operating Officer) EUR 1,371,390 on September 13, 2021. In all, 156 sales worth EUR 65,746,977 (median EUR 208,533) against 7 purchases worth EUR 735,432 (median EUR 23,739), so purchases are 4%.
Salvatore Privitera (Chief Technical Officer) bought EUR 102,673 on May 30, 2024. On March 1, 2018, two filers bought EUR 173,460.
Read moreShow less
This US healthcare and pharma company, valued at USD 2.9 billion and 3.8% held by its insiders, has 654 filings published from January 5, 2016 to September 24, 2026, including 359 grants and 89 option exercises. Michael H. Carrel signed 129. The yearly peak is 101 filings in 2020. The last twelve months hold 62, with 16 sales and no purchase.
